Exploring new treatment targets for cancers with RAS mutations
Interrogating the RAS interactome for therapeutic vulnerabilities
This study is looking at how certain proteins, especially one called PIP5K1A, interact with RAS genes that are often mutated in cancer, with the goal of finding new ways to improve treatments for people with RAS-driven cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11003970 on NIH RePORTER |
What this research studies
This research investigates the RAS genes, which are frequently mutated in various cancers, making them difficult to treat. The team uses a novel technique to identify proteins that interact with RAS, aiming to uncover new therapeutic targets. By focusing on a specific protein called PIP5K1A, which promotes cancer growth in RAS-mutant cells, the researchers hope to develop targeted therapies that could enhance the effectiveness of existing cancer treatments. This approach could lead to more effective strategies for managing RAS-driven cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that have mutations in the RAS genes, such as KRAS, NRAS, or HRAS.
Not a fit: Patients with cancers that do not involve RAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with RAS-mutant cancers, improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in targeting RAS-related pathways, but this specific approach focusing on the RAS interactome is relatively novel.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Adhikari, Hema — Washington University
- Study coordinator: Adhikari, Hema
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.